# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN
- Date: 2026-09-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic preventive visit; no new complaints. **S**

## History of present illness

Mr. Washington comes for his periodic preventive visit. He completed the health risk assessment before the visit. The back strain from August cleared in about ten days with heat, walking, and acetaminophen, and he has taken no NSAIDs since. His home blood pressures over the past two weeks have averaged in the low 120s systolic. His headaches have not returned and his concentration is better than in the spring, although he still tires by evening on travel days. He has had no emergency visits or hospital stays. He takes his four blood pressure and kidney medicines and his statin from a weekly organizer and has added no over-the-counter medicines or supplements. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 59 |
| Interval history | Lumbar strain in August, resolved without NSAIDs or imaging |
| Blood pressure at home | Averaging in the low 120s systolic |
| Medicines | Adherent with a weekly organizer; no NSAIDs or new over-the-counter products |
| Active conditions | Hypertensive chronic kidney disease stage G3b A3, hypertensive retinopathy, mild anemia of chronic kidney disease, and hyperlipidemia |
| Functional status | Independent in all activities; tires by evening on travel days |

## Health risk assessment

Completed by the patient before the visit and reviewed during the visit. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, and better than in the spring |
| Psychosocial | Lives with his spouse; close family and colleagues; work and travel are heavy, and he feels the strain but not low mood |
| Tobacco | Never smoker |
| Alcohol | A drink a few times a year; AUDIT-C score 1 |
| Physical activity | Walks 20 to 30 minutes on most days at home, less when traveling; about 120 minutes a week |
| Nutrition | Low-sodium meals at home; chooses lower-sodium dishes when eating on the road, with mixed success |
| Sleep | About six hours on work nights; no snoring or daytime sleepiness reported |
| Activities of daily living | Independent in all activities of daily living |
| Instrumental activities of daily living | Manages his own medicines, finances, correspondence, and travel |
| Home and travel safety | Smoke detectors working; wears a seat belt; no firearms in the home |
| Hearing and vision | Reading glasses; dilated eye examination in May; no hearing concerns |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by evening on travel days; weight stable; no fever or night sweats |
| Eyes | Negative | No new blurring, floaters, or loss of vision |
| Ears, nose, mouth, and throat | Negative | No hearing loss or hoarseness |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Occasional indigestion when traveling, unchanged; no difficulty swallowing, blood in the stool, or black stool |
| Genitourinary | Negative | Nighttime urination once; no weak stream, dysuria, or blood in the urine |
| Musculoskeletal | Negative | Back pain from August resolved; no joint pain |
| Integumentary | Negative | No rashes or genital symptoms on dapagliflozin |
| Neurological | Negative | Headaches resolved; concentration improved; no weakness, numbness, or dizziness on standing |
| Psychiatric | Negative | Mood steady; PHQ-9 score 2 |
| Endocrine | Negative | No polyuria, polydipsia, or heat or cold intolerance |
| Hematologic | Negative | No easy bruising or bleeding |

13 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 70.4 kg; BMI 24.4 kg/m². All vital signs are synthetic.

PHQ-9: 2; AUDIT-C: 1. All results are synthetic.

## Change since baseline

- PHQ-9: 4 at baseline, 2 at this visit **S**

## Immunizations given today

- Influenza vaccine, 2026-2027 season **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Alert, well-appearing, and articulate; weight 70.4 kg, BMI 24.4 |
| Eyes | Undilated funduscopy shows arteriolar narrowing and arteriovenous nicking, unchanged; no hemorrhages, exudates, or disc swelling |
| Ears, nose, and throat | Canals and tympanic membranes normal; oropharynx clear |
| Neck | No thyroid enlargement or nodes; no carotid bruits |
| Cardiovascular | Regular rhythm, rate 72; apical impulse not displaced; no murmur; pedal pulses normal; no edema |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; no masses or renal bruit |
| Musculoskeletal | Full, pain-free lumbar range of motion; no paraspinal spasm |
| Skin | No rashes or suspicious lesions |
| Neurological | Alert and oriented; strength, sensation, and gait normal |
| Psychiatric | Euthymic and engaged; judgment and insight intact |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic preventive visit, age 59**. Health risk assessment reviewed and a written prevention plan given. Depression and alcohol screens are negative. His kidney disease shapes several preventive choices: vaccines, the colonoscopy preparation, and avoiding NSAIDs. **S**
   - Next preventive visit in one year.
2. **Severe hypertension with hypertensive kidney disease** (I12.9). Blood pressure 122/76 mmHg, below 130/80 and close to the KDIGO systolic target below 120 when tolerated; no orthostatic symptoms. **S**
   - Continue amlodipine, losartan, and chlorthalidone; standardized office reading at the six-month review in October.
3. **Chronic kidney disease stage G3b A3** (N18.32). eGFR 30 in August, stable; UACR 360 mg/g in June, down from 820. **S**
   - Continue losartan and dapagliflozin.
   - eGFR, UACR, hemoglobin, calcium, phosphate, PTH, and the kidney failure risk score at the October review, on the CMID schedule.
4. **Hyperlipidemia** (E78.5). On moderate-intensity atorvastatin, as recommended for adults 50 and older with chronic kidney disease. **S**
   - Continue atorvastatin 20 mg; no repeat LDL, per KDIGO.
5. **Hypertensive retinopathy, both eyes** (H35.033). Unchanged on undilated funduscopy; no symptoms. **S**
   - Next dilated eye examination in May.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Influenza vaccine | Completed today | This season's vaccine given today |
| Recombinant zoster vaccine | Completed today | Dose 1 of 2 given today; dose 2 due in two to six months |
| COVID-19 vaccine | Due | Discussed; he plans to get this season's vaccine at his pharmacy |
| RSV vaccine | Due | Discussed because chronic kidney disease increases his risk of severe RSV illness; he will decide at the pharmacy visit |
| Pneumococcal vaccine | Up to date | PCV20 given in May; no further doses needed |
| Hepatitis B vaccine | Up to date | Two-dose HepB-CpG series completed in June |
| Tetanus booster | Up to date | Tdap seven years ago; next booster due in about three years |
| Colorectal cancer screening | Referred | No prior screening on record; he chose colonoscopy. Referral sent with a request for a polyethylene glycol preparation and no sodium phosphate preparation, because of his kidney disease; hold dapagliflozin and chlorthalidone on the preparation day |
| Prostate cancer screening | Ordered | Shared decision-making about benefits, false positives, and overdiagnosis, including the higher prostate cancer risk among Black men described in the USPSTF statement. He chose PSA testing; added to the October blood draw |
| Hepatitis C and HIV screening | Ordered | One-time screening offered to all adults in these age ranges, not based on any individual risk; no prior result on record; added to the October blood draw |
| Blood pressure, cholesterol, and diabetes screening | Up to date | Treated hypertension; on statin therapy; HbA1c 5.4 percent in May |
| Depression screening | Completed today | PHQ-9 score 2 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 1 |
| Tobacco use | Completed today | Never smoker |
| Physical activity and diet | Completed today | Counseled to reach 150 minutes of walking a week and to keep sodium below 2 g a day when traveling |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never smoker |
| Eye examination | Up to date | Dilated examination in May; repeat yearly for hypertensive retinopathy |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with his consent, prompted by his chronic kidney disease. He has named a health care agent and has a written health care directive; a copy is now in the chart. He wants full treatment for reversible illness, including hospital care. He asked to learn more about the options if his kidney function falls further, including dialysis and conservative care, and that discussion will continue with nephrology. He will review these wishes with his agent. **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (KDIGO)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (KDIGO)
- CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force
- Prostate Cancer: Screening (2018), U.S. Preventive Services Task Force

## Follow-up

- Colonoscopy referral sent; PSA and hepatitis C and HIV screening with the October blood draw. Zoster vaccine dose 2 in two to six months. Six-month blood pressure and kidney review in October. Next preventive visit in one year. **S**
- Next scheduled visit 2026-10-26: six-month blood pressure and chronic kidney disease review. **S**
